Alpha-Lipoic Acid

PubMed ID: 15529636

Open RCT increased antioxidant enzyme markers (SOD, total antioxidant capacity) in diabetics on ALA.

PubMed ID: 17999779

Randomized trial in healthy men: ALA reduced exercise-induced TBARS and improved antioxidant enzyme responses.

PubMed ID: 18315507

6-month RCT in HIV patients restored whole-blood glutathione (major intracellular antioxidant) vs placebo.

PubMed ID: 19105409

Combination therapy including ALA reduced lipid peroxidation and increased antioxidant enzyme activity.

PubMed ID: 19617657

Resistance-trained men: marked reductions in oxidative damage markers and increases in glutathione-related antioxidants after ALA.

PubMed ID: 20034232

Short-term oral ALA increased total antioxidant status and reduced lipid/protein oxidation after exercise.

PubMed ID: 21848849

Preclinical sow study showed increased GSH‑Px and decreased MDA with dietary ALA (animal data).

PubMed ID: 21255807

IV ALA reduced TBARS (oxidative marker) and improved endothelial function acutely.

PubMed ID: 22678104

R‑ALA increased serum SOD activity in AMD patients (randomized, modest clinical implication).

PubMed ID: 22431837

Antioxidant combo including ALA lowered CSF F2‑isoprostanes (~19%) despite mixed clinical outcomes.

PubMed ID: 22353612

Acute oral antioxidant cocktail including ALA reduced TBARS and increased SOD activity in older adults.

PubMed ID: 23444750

Antioxidant mixture containing ALA increased SOD and modestly affected BMD in postmenopausal women (small effect).

PubMed ID: 23044303

Addition of lipoic acid to glycemic therapy reduced oxidative marker (8‑iso‑PGF2α) in obese T2DM patients.

PubMed ID: 24172699

4‑month ALA in young T1D increased glutathione and decreased MDA/TNF‑α (consistent antioxidant improvements).

PubMed ID: 24241092

ALA+vitamin E showed some anti‑inflammatory/nutritional benefits and minor antioxidant changes.

PubMed ID: 24240384

Adding ALA during ECC lowered inflammatory markers and is consistent with reduced oxidative/inflammatory stress.

PubMed ID: 23485514

Daily ALA improved total antioxidant capacity (TAC) in RRMS patients.

PubMed ID: 24491880

Combination reduced MDA (lipid peroxidation) in diabetic nephropathy patients.

PubMed ID: 24324045

Acute antioxidant cocktail including ALA reduced free‑radical EPR signal and improved antioxidant markers.

PubMed ID: 25535146

Increased SOD and GSH‑Px and decreased MDA in post‑stroke elderly—clear antioxidant enzyme changes.

PubMed ID: 24821457

High‑dose LA reduced several pro‑inflammatory cytokines, consistent with antioxidative/anti‑inflammatory effects.

PubMed ID: 27901334

2‑week ALA in diabetic neuropathy raised SOD and lowered MDA (antioxidant marker changes).

PubMed ID: 27801825

Multi‑ingredient supplement containing ALA raised antioxidant enzymes and lowered MDA in T2D RCT; effect attribution partly to ALA.

PubMed ID: 27840374

In dry AMD RCT oral ALA increased serum SOD activity and improved antioxidant indices.

PubMed ID: 28258730

Post‑AF ablation ALA lowered CRP, TNF‑α and nitrotyrosine (oxidative/inflammatory markers) vs placebo.

PubMed ID: 28116765

IV ALA produced robust reductions in MDA and increases in SOD/TAC in early diabetic kidney disease (direct antioxidant biomarker effects).

PubMed ID: 30585337

In obese NAFLD, ALA lowered IL‑6 and raised adiponectin with some antioxidant/anti‑inflammatory signal (but no steatosis change).

PubMed ID: 30286558

In ICU patients ALA significantly increased total antioxidant capacity (TAC) vs control.

PubMed ID: 30311825

Multi‑nutrient supplement including ALA lowered oxidative hydroperoxides and other oxidative markers in diabetics.

PubMed ID: 29974521

Liver transplant pilot: ALA reduced reperfusion‑linked alarmins and hypoxia/oxidative signatures (less reperfusion injury).

PubMed ID: 30303695

GDM trial: ALA increased adiponectin and improved MDA/TAC ratio (direct antioxidant marker improvement).

PubMed ID: 30987551

Hemodialysis RCT found ALA increased SOD activity vs placebo (improved antioxidant enzyme activity).

PubMed ID: 31564281

Short-term adjunct ALA lowered hs-CRP and TNF-α (inflammatory/oxidative milieu).

PubMed ID: 31291793

Directly increased antioxidant enzyme expression/activity and lowered ROS in a randomized trial.

PubMed ID: 31243641

Multi‑ingredient eye supplement including ALA improved macular electrophysiology (likely antioxidant mix effect).

PubMed ID: 32692358

R-ALA increased HMOX1 and decreased urinary F2-isoprostanes (oxidative stress marker).

PubMed ID: 32256955

In T2D, ALA reduced oxidized‑LDL and pro‑atherogenic Lp‑PLA2 (oxidative stress–related biomarkers).

PubMed ID: 34699040

Clinical poisoning study: ALA ± vitamin C reduced oxidative‑stress markers vs routine care.

PubMed ID: 34105866

Reduced MDA (oxidative marker) and CRP in migraine patients vs placebo.

PubMed ID: 34369837

Gestational diabetes RCT increased total antioxidant capacity and antioxidant enzymes.

PubMed ID: 35596774

Chemotherapy trial reported lowered oxidative/inflammatory markers alongside neuroprotection.

PubMed ID: 35442486

Large RCT showed reductions in 8‑OHdG and inflammatory markers — direct antioxidant biomarker improvements.

PubMed ID: 34997178

Migraine trial lowered serum lactate/VCAM‑1 indicating improved mitochondrial/endothelial oxidative status.

PubMed ID: 10569644

Healthy-adult trial showed reduced lipid/protein oxidation and lowered F2-isoprostanes.

PubMed ID: 9285502

Combined trials reported oxidative-stress improvements with ALA in diabetics (modest evidence).

PubMed ID: 8786016

Large RCT included antioxidant outcomes alongside neuropathy benefit (ALA has antioxidant activity).

PubMed ID: 8390768

Diabetic trial reported reduced oxidative-stress markers with ALA-containing antioxidant therapy.

PubMed ID: 23238616

IV ALA rapidly increased ALDH2 activity and lowered 8‑iso‑PGF2α, direct antioxidant evidence.

PubMed ID: 10441861

IV ALA improved oxidative markers vs placebo.

PubMed ID: 32299733

Antioxidant mix including ALA improved embryo quality in culture media (mechanistic antioxidant context).

PubMed ID: 31535807

Multi-ingredient antioxidant complex (includes ALA) markedly lowered sperm oxidative stress and DNA damage.

PubMed ID: 39340853

Combination study reported decreased MDA and increased SOD with ALA added.

PubMed ID: 41191982

Monotherapy ALA reduced MDA (oxidative stress) markers in T1D nephropathy — strong direct antioxidant evidence.

PubMed ID: 23827078

In diabetic neuropathy, adding ALA to intensive insulin improved inflammatory/adipokine markers—supports neuropathy care.

PubMed ID: 18598095

Randomized trial: thioctic acid improved sciatica symptom scores, EMG, and reduced analgesic need vs ALC over 60 days.

PubMed ID: 33114210

12-month multi-ingredient tablet including ALA improved neuropathic pain and sural nerve conduction in type 2 diabetes.

PubMed ID: 38138300

Rehab + supplements (including ALA) produced large reductions in sciatica pain and improved QoL (neuropathic component).

PubMed ID: 37366197

Multi‑ingredient nutraceutical containing ALA reduced carpal tunnel symptoms and pain vs control.

PubMed ID: 10441861

IV ALA produced marked symptomatic improvement in diabetic neuropathy vs placebo.

PubMed ID: 12473978

Open trial reported benefit for burning mouth symptoms (neuropathic pain) with ALA.

PubMed ID: 15002318

Comparative study in alcohol neuropathy showed ALA produced better symptom and electrophysiologic improvements than B1.

PubMed ID: 39339645

6‑month combination tablet (includes ALA) produced substantial pain relief and some nerve‑function gains in diabetic neuropathy.

PubMed ID: 31701699

12‑week RCT in painful diabetic neuropathy showed clinically relevant pain reductions with ALA 600 mg/day.

PubMed ID: 8390768

Diabetic patients showed improved thermo- and vibration sensitivity with antioxidant therapy including ALA.

PubMed ID: 8786016

Large RCT: IV ALA substantially reduced neuropathic pain and symptoms (strong clinical evidence).

PubMed ID: 9285502

Pooled trials demonstrated significant reductions in neuropathic symptoms with ALA.

PubMed ID: 10499773

Two-year randomized data showed objective improvements in nerve conduction in diabetic polyneuropathy.

PubMed ID: 10480774

IV then oral ALA produced small early symptom benefits and some improvement in neuropathy deficit scores.

PubMed ID: 12110042

Double-blind RCT found durable symptomatic benefit for burning mouth syndrome with ALA.

PubMed ID: 12610036

Large double-blind RCT showed clinically meaningful symptomatic improvement in diabetic polyneuropathy with IV ALA.

PubMed ID: 15529636

ALA improved autonomic neuropathy measures in type 1 diabetics (nerve function benefit).

PubMed ID: 17065669

Large RCT: oral ALA (600 mg/day) produced clinically meaningful reductions in symptoms of diabetic distal symmetric polyneuropathy.

PubMed ID: 18167250

Intravenous ALA for 14 days produced rapid, significant improvement in sensory symptoms and neuropathy screening scores.

PubMed ID: 19105409

Study of ALA + mildronate showed improved neuropathy scores and nerve electrophysiology versus control (combination therapy).

PubMed ID: 21092474

Large RCT (1800 mg/day) over 12 weeks produced marked reductions in diabetic neuropathy symptom scores vs placebo.

PubMed ID: 20701667

Small randomized study found ALA reduced burning mouth syndrome symptoms vs control (active-treatment groups overall beneficial).

PubMed ID: 20711135

Large RCT: combination ALA+gabapentin produced highest responder rate for burning mouth (confounded by combination therapy).

PubMed ID: 21775755

Large 4‑year RCT showed modest but clinically meaningful improvements in neuropathic impairment and responder rates.

PubMed ID: 25535146

Post‑stroke patients showed neurologic improvement (NIHSS) and antioxidant changes after ALA, consistent with nerve support.

PubMed ID: 24477618

Oral ALA+SOD added to physiotherapy significantly reduced neck pain and disability—clinical nerve/pain comfort benefit.

PubMed ID: 26034927

RCT in burning mouth syndrome (neuropathic oral pain) showed 64% clinical improvement vs 27.5% placebo with ALA 600 mg/d.

PubMed ID: 26651260

Large 4‑year diabetic neuropathy trial (post‑hoc analysis) shows ALA 600 mg/day associated with neuropathy improvement/prevention over long term.

PubMed ID: 26345602

Enrichment RCT: responders to high‑dose ALA who continued oral ALA had reduced neuropathic symptoms, improved vibration sense and less analgesic use.

PubMed ID: 27901334

Two‑week ALA improved neuropathic symptom scores and vibration sense in diabetic peripheral neuropathy.

PubMed ID: 28249792

Post‑op carpal tunnel RCT: ALA did not change conduction but reduced pillar pain incidence after surgery.

PubMed ID: 32370731

Large RCT: oral ALA (600 mg twice daily) over 6 months improved neuropathic pain, NSS and vibration perception in diabetic neuropathy.

PubMed ID: 34649217

Randomized trial: oral ALA (400–800 mg/day) reduced idiopathic pain scores vs placebo over 2 months (well tolerated).

PubMed ID: 34128884

Adding oral ALA to pulsed radiofrequency improved pain and function in chronic lumbar radicular pain (large randomized open study).

PubMed ID: 35596774

600 mg/day ALA reduced incidence and severity of chemo‑induced peripheral neuropathy in randomized trial.

PubMed ID: 35548968

ALA + ipidacrine reduced paclitaxel‑induced neuropathy severity clinically.

PubMed ID: 36811539

ALA + ipidacrine preserved sensory nerve ENMG measures during paclitaxel — objective neuroprotection.

PubMed ID: 37678556

ALA reduced neuropathic pain vs baseline, though less effective than pregabalin and no additive benefit when combined.

PubMed ID: 39340853

ALA added to tanshinone IIA improved nerve conduction and neuropathy metrics vs comparator.

PubMed ID: 38764099

Acupuncture + thioctic acid improved clinical neuropathy scores and nerve conduction vs drug alone.

PubMed ID: 40084800

Oral ALA (200 mg TID) produced large, significant pain relief in burning mouth syndrome (monotherapy arm).

PubMed ID: 40501262

Combination nutraceuticals including ALA produced marked improvements in neuropathy symptoms and nerve conduction; attribution to ALA limited.

PubMed ID: 23238616

Lowered oxidative stress marker (8‑iso‑PGF2α) in ACS patients, indicating reduced cellular oxidative damage.

PubMed ID: 35596774

Randomized trial showed reduced chemotherapy‑induced neuropathy and lowered BNP — clear cellular/tissue protection.

PubMed ID: 34699040

ALA (±vitamin C) reduced oxidative-stress markers in acute amitriptyline poisoning—mitigated cellular oxidative injury.

PubMed ID: 32769849

CMX-2043 (ALA-derivative) given before PCI reduced myocardial injury biomarkers (cell protection signal; derivative rather than dietary ALA).

PubMed ID: 32256955

ALA reduced ox‑LDL and Lp‑PLA2—markers of oxidative damage to lipoproteins and vascular cells.

PubMed ID: 31291793

Lowered sperm ROS and increased GST expression/activity—direct evidence of cellular protection from oxidative damage.

PubMed ID: 31564281

Adjunctive ALA reduced inflammatory markers and urinary albumin excretion in early diabetic kidney disease (renal cell protection).

PubMed ID: 10499773

Two-year data showed preservation/improvement of sensory nerve conduction (tissue protection).

PubMed ID: 8390768

Trial reported decreases in oxidative-stress markers and urinary albumin with antioxidant therapy including ALA.

PubMed ID: 35442486

Reduced oxidative damage marker (8‑OHdG) and inflammation in diabetic HD patients supports cellular protection.

PubMed ID: 32299733

Antioxidant supplementation (including ALA) in IVF culture improved embryo quality, implying reduced cellular damage in embryos.

PubMed ID: 31535807

Multi‑ingredient antioxidant complex with ALA produced large reductions in sperm oxidative stress and DNA fragmentation.

PubMed ID: 41400270

Significant reductions in TNF-α, CRP, and TGF-β1 imply reduced inflammatory and profibrotic cell damage.

PubMed ID: 39340853

Combination therapy improved oxidative stress and nerve conduction vs comparator, consistent with protection.

PubMed ID: 37462489

Significant reduction in sperm DNA fragmentation (DFI) when ALA was combined with a decoction.

PubMed ID: 36811539

ENMG data in chemo patients preserved sensory nerve AP amplitude/duration/area indicating reduced axonal damage.

PubMed ID: 35548968

Paclitaxel trial combining ALA reduced severity of CIPN (less nerve damage clinically).

PubMed ID: 30303695

GDM trial showed improved antioxidant balance (MDA/TAC), implying reduced oxidative cellular damage.

PubMed ID: 29974521

Peri‑transplant ALA reduced reperfusion injury markers and PRS events, showing protection against ischemia–reperfusion damage.

PubMed ID: 18315507

Restoration of intracellular glutathione and improved lymphocyte function suggest cellular protection in HIV patients.

PubMed ID: 30311825

Multi‑agent supplement with ALA improved oxidative markers and platelet aggregation—consistent with reduced oxidative cellular stress.

PubMed ID: 28116765

IV ALA decreased urinary albumin excretion and oxidative markers in early diabetic nephropathy—direct evidence of cellular protection in kidneys.

PubMed ID: 28258730

ALA reduced plasma nitrotyrosine (oxidative damage marker) and inflammatory cytokines after AF ablation.

PubMed ID: 27840374

In dry AMD, increased SOD activity and improved visual outcomes indicate protection of retinal cells against oxidative damage.

PubMed ID: 25535146

Decreased MDA and increased antioxidant enzymes with improved neurological scores—cell protection after stroke.

PubMed ID: 24324045

Antioxidant cocktail including ALA reduced free radicals and improved vascular biomarkers, consistent with cell protection.

PubMed ID: 41191982

ALA reduced MDA (oxidative stress) and urine albumin excretion, indicating cellular/renal protection.

PubMed ID: 19231043

Subgroup decreases in MDA and protein carbonyls in healthy AA subjects — biochemical evidence of reduced oxidative damage.

PubMed ID: 19617657

ALA reduced lipid and protein oxidation after exercise, indicating cellular protection from oxidative damage.

PubMed ID: 20034232

Short-term ALA decreased TBARS and protein carbonylation, markers of lipid/protein oxidative damage.

PubMed ID: 24491880

Reduced albuminuria and MDA in diabetic nephropathy, indicating renal cellular protection.

PubMed ID: 23485514

TAC improved though other oxidative markers unchanged—partial cellular protection evidence.

PubMed ID: 24240384

Reduced perioperative inflammatory markers (IL‑6/8, complement) implies reduced procedural cellular injury.

PubMed ID: 24172699

In young T1D ALA increased glutathione, decreased MDA/TNF‑α and improved LV function—cardioprotective/ cellular protection.

PubMed ID: 22374556

Oral ALA prevented an increase in lipid peroxidation in T2DM over 6 months (protective effect on lipids).

PubMed ID: 21255807

IV ALA improved endothelial function and reduced TBARS (less oxidative damage to endothelium).

PubMed ID: 17999779

Reduced exercise-induced lipid peroxidation and preserved antioxidant enzymes after ALA supplementation.

PubMed ID: 10569644

Markers of lipid and protein oxidation decreased in healthy adults on ALA.

PubMed ID: 30311825

Multi‑ingredient trial with ALA showed lowered fasting glucose and large HbA1c improvement in obese diabetics (supports metabolic benefit; multi‑ingredient caveat).

PubMed ID: 30328246

In gestational diabetes 100 mg/day ALA for 8 weeks lowered fasting glucose and some liver enzymes (metabolic endpoints improved).

PubMed ID: 36963888

NAFLD study combining supplements including ALA improved steatosis and anthropometrics (multi‑component intervention).

PubMed ID: 23981814

Inositol+ALA improved HOMA‑IR and lipids in metabolic syndrome (combination product, strong RCT signal).

PubMed ID: 10468203

Placebo‑controlled trial showed ~27% improvement in insulin-stimulated glucose disposal (strong metabolic signal).

PubMed ID: 11951812

Controlled‑release ALA improved exposure and significantly lowered fructosamine in T2D (glycemic benefit).

PubMed ID: 15655130

4-week RCT in metabolic-syndrome patients improved endothelial function and lowered IL-6/PAI-1, relevant to metabolic health.

PubMed ID: 21666939

8‑week oral ALA (300 mg/day) improved fasting/postprandial glucose and reduced HOMA‑IR in T2DM (randomized trial).

PubMed ID: 21187189

High‑dose ALA (1800 mg/day) produced modest weight loss in obese adults, indicating metabolic/energy‑balance impact.

PubMed ID: 22374556

6‑month oral ALA produced dose‑related small decreases in fasting glucose and HbA1c in T2DM (modest metabolic benefit).

PubMed ID: 23044303

In obese newly diagnosed T2DM lipoic acid treatment added to glycemic therapy produced further decreases in adipokines and oxidative markers (supportive).

PubMed ID: 23905488

T2DM men had improved HbA1c and BMI over 12 weeks with ALA—strong metabolic benefit.

PubMed ID: 23827078

In diabetic neuropathy patients ALA + intensive insulin improved adipokine regulation and reduced inflammatory markers.

PubMed ID: 24442048

Multi‑ingredient supplement including ALA improved HDL and triglycerides in psoriasis patients as an adjunct.

PubMed ID: 25535146

Post‑stroke elderly diabetics had improved glucose, HOMA‑IR and lipid measures after ALA—metabolic improvement.

PubMed ID: 25594166

Overweight/obese women on calorie restriction lost slightly more weight with ALA—helps metabolic weight outcomes.

PubMed ID: 26171398

Antioxidant diet + ALA reduced insulin requirement transiently and improved endothelial health, supporting metabolic benefits.

PubMed ID: 25753493

12‑week RCT in chronic SCI men: ALA 600 mg/d lowered fasting glucose, weight and waist and BP though dietary intake fell too (confounder).

PubMed ID: 27801825

Large RCT of multi‑ingredient supplement including ALA in T2D improved FPG/PPG/HbA1c and HOMA‑IR—strong metabolic signal (multicomponent).

PubMed ID: 28537012

Combined nutraceutical including ALA improved fasting glucose and HOMA‑IR in impaired fasting glucose subjects.

PubMed ID: 30286558

In critically ill patients ALA lowered glucose and mitigated HOMA‑IR changes acutely.

PubMed ID: 29743087

Randomized trial in overweight women: ALA significantly enhanced weight/fat loss and improved HOMA‑IR—strong metabolic benefit.

PubMed ID: 30303695

In GDM women ALA increased adiponectin and reduced HOMA‑IR and MDA/TAC ratio (direct metabolic improvements).

PubMed ID: 31343010

12-week ALA improved insulin resistance and favourable adipokine profile in obese NAFLD patients.

PubMed ID: 32692358

R-ALA reduced oxidative stress markers and produced modest BMI reduction in overweight adults.

PubMed ID: 32256955

1200 mg/day ALA in type 2 diabetes lowered ox-LDL, Lp-PLA2 mass and triglycerides (favourable metabolic/cardiometabolic markers).

PubMed ID: 34369837

In gestational diabetes, ALA 300 mg/day improved fasting glucose and antioxidant indices (metabolic benefit).

PubMed ID: 35442486

6‑month RCT in diabetic hemodialysis patients showed improved FBG, HbA1c, reduced inflammation and better anemia metrics with ALA.

PubMed ID: 37686725

12‑week MIS containing ALA produced modest weight/fat loss and improved hepatic molecular markers.

PubMed ID: 39340853

ALA + tanshinone improved glucose and lipids vs comparator in diabetic neuropathy patients.

PubMed ID: 41191982

ALA reduced HbA1c significantly in T1D nephropathy, directly supporting metabolic (glycemic) control.

PubMed ID: 41400270

In diabetic ischemic cardiomyopathy, ALA reduced inflammatory/profibrotic markers and improved cardiac measures, supporting circulatory health.

PubMed ID: 39641383

Randomized trial showed ALA increased inhibition of platelet aggregation (collagen/ADP pathways) — direct circulatory effect.

PubMed ID: 32769849

ALA-derivative reduced peri-procedural myocardial injury biomarkers (myocardial protection; derivative agent).

PubMed ID: 23238616

In ACS patients IV ALA increased ALDH2 and reduced oxidative stress—mechanistically cardioprotective and circulation supportive.

PubMed ID: 9285502

Reported modest improvements in some cardiac autonomic (HRV) parameters with oral ALA.

PubMed ID: 15529636

Improved cardiovascular autonomic neuropathy score, Valsalva ratio and orthostatic BP change with ALA (type 1 diabetes).

PubMed ID: 15655130

Metabolic-syndrome RCT: ALA produced a ~44% improvement in flow‑mediated vasodilation (endothelial function).

PubMed ID: 24240384

ALA added to ECC lowered inflammatory mediators after cardiac surgery, potentially protecting vascular function.

PubMed ID: 26171398

Antioxidant diet + ALA significantly improved endothelial function (RHI) in adolescents with type 1 diabetes—direct circulatory benefit.

PubMed ID: 26347218

600 mg ALA improved cardiac sympathetic innervation imaging (MIBG) at 12 months in takotsubo survivors—circulatory/autonomic signal.

PubMed ID: 27735021

Combination alprostadil + ALA improved erectile scores and endothelial function vs tadalafil—endothelial/circulatory improvement noted.

PubMed ID: 28258730

Post‑ablation reductions in inflammatory/oxidative markers could benefit vascular health even though AF recurrence was unchanged.

PubMed ID: 28116765

IV ALA improved FMD (endothelial function) and other vascular markers in early diabetic kidney disease.

PubMed ID: 30311825

Reduced platelet aggregation in obese diabetics (with ALA in combo) suggests improved circulatory/hemorheologic parameters.

PubMed ID: 30759784

800 mg/day ALA for 12 weeks increased basal and peak brachial artery diameters in overweight/obese youth (direct vasodilatory/vascular effect).

PubMed ID: 31564281

Adjunctive ALA reduced systemic inflammation and urinary albumin excretion (markers relevant to vascular/kidney health).

PubMed ID: 22353612

Acute antioxidant cocktail including ALA restored endothelial FMD in older adults (age‑dependent vascular benefit; combo product).

PubMed ID: 24172699

ALA improved subclinical LV systolic function and reduced inflammatory markers in young T1D subjects, indicating cardiovascular benefit.

PubMed ID: 32256955

ALA reduced pro-atherogenic biomarkers (ox-LDL, Lp-PLA2) and triglycerides in type 2 diabetes—supports vascular health.

PubMed ID: 24324045

Acute antioxidant cocktail including ALA improved flow‑mediated dilation and reduced pulse‑wave velocity in COPD patients—strong vascular function signal.

PubMed ID: 18070144

Acute ALA before OGTT partially prevented glucose-induced endothelial dysfunction in impaired‑glucose-tolerance subjects.

PubMed ID: 17259696

In diabetics on hemodialysis, ALA lowered ADMA, an established marker of endothelial dysfunction.

PubMed ID: 20050880

IV ALA improved endothelium-dependent vasodilation in T2D in a randomized trial (clear physiologic effect).

PubMed ID: 20162509

Oral ALA over 3 weeks improved flow-mediated dilation and reduced TBARS in women with subclinical hypothyroidism (randomized study).

PubMed ID: 17396066

Combined ALA + acetyl‑L‑carnitine increased brachial artery diameter and lowered systolic BP in higher‑risk CAD subgroups.

PubMed ID: 20004356

IV ALA reduced ADMA, an endothelial dysfunction biomarker, in T2D (randomized study).

PubMed ID: 21255807

IV ALA improved endothelium‑dependent arterial dilation and substantially lowered TBARS in impaired fasting glucose subjects (strong short‑term effect).

PubMed ID: 21750253

Adding 600 mg/day ALA to quinapril markedly improved FMD and halved urinary albumin vs quinapril alone (crossover RCT in diabetic HTN).

PubMed ID: 22228743

600 mg/day ALA reduced platelet activation measures in T1D, implying improved vascular/hemocompatibility.

PubMed ID: 31564281

ALA added to valsartan reduced hs-CRP and TNF-α rapidly in early diabetic kidney disease (anti-inflammatory effect).

PubMed ID: 24241092

ALA with vitamin E reduced IL‑6 and improved malnutrition in hemodialysis patients—some immune/inflammatory benefit.

PubMed ID: 24240384

Adding ALA during extracorporeal circulation lowered IL‑6/IL‑8 and complement components—robust anti‑inflammatory effects perioperatively.

PubMed ID: 23827078

In diabetic neuropathy, adding ALA to insulin improved TNF‑α and hs‑CRP and adipokine regulation—immune/inflammatory modulation.

PubMed ID: 25535146

Increased antioxidant enzymes and reduced oxidative stress with clinical improvement post‑stroke imply improved resilience.

PubMed ID: 24821457

12 weeks of 1,200 mg/day ALA significantly lowered multiple inflammatory cytokines in RRMS versus placebo.

PubMed ID: 27718765

Vaginal ALA increased cervical anti‑inflammatory cytokines and prevented cervical shortening in women after preterm labor—direct immune/anti‑inflammatory signal.

PubMed ID: 27869661

Probiotic + ALA reduced circulating endotoxin and gut permeability after heavy exercise, an effect that supports mucosal/systemic immune resilience.

PubMed ID: 28258730

ALA reduced CRP and TNF‑α after AF ablation, indicating anti‑inflammatory effects relevant to immune resilience.

PubMed ID: 30585337

In obese NAFLD ALA lowered IL‑6 and raised adiponectin, indicating reduced inflammatory tone.

PubMed ID: 41400270

Significant reductions in TNF-α and CRP indicate ALA may modulate inflammatory mediators relevant to immune resilience.

PubMed ID: 35442486

Significant reductions in hs‑CRP and TNF‑α in diabetic hemodialysis patients indicate anti‑inflammatory/immunomodulatory effects.

PubMed ID: 35596774

Reduction in inflammatory markers in chemo patients suggests some immune‑protective modulation.

PubMed ID: 34105866

ALA reduced CRP in episodic migraineurs, indicating an anti-inflammatory effect relevant to immune resilience.

PubMed ID: 33487271

Probiotic+ALA arm lowered CRP and improved weight maintenance (reduced systemic inflammation).

PubMed ID: 32256955

ALA lowered Lp‑PLA2 and ox‑LDL (pro‑inflammatory/pro‑atherogenic biomarkers) in T2D.

PubMed ID: 29974521

Lower peri‑reperfusion alarmins and inflammation transcripts with ALA suggest modulation of innate inflammatory responses.

PubMed ID: 18315507

6-month RCT in HIV: restored glutathione and improved lymphocyte proliferation—direct immunologic improvements.

PubMed ID: 21908204

8‑week ALA in hemodialysis patients significantly lowered hsCRP (anti‑inflammatory), suggesting improved immune/inflammatory resilience.

PubMed ID: 24172699

ALA decreased TNF‑α and other inflammatory markers in young T1D, supporting immune/inflammatory modulation.

PubMed ID: 18315507

Restored intracellular glutathione and improved lymphocyte responses over 6 months in HIV patients, suggesting better physiological resilience.

PubMed ID: 33514891

Restoration of near vision can improve daily function and perceived vitality in older adults.

PubMed ID: 38138300

Large rehab + supplement trial (includes ALA) produced meaningful pain reduction and QoL gains — broad vitality effect in that setting.

PubMed ID: 37686725

12‑week multi‑ingredient study including ALA produced modest weight/fat loss and improved liver markers, supporting vitality.

PubMed ID: 37462489

Jujing decoction + ALA improved multiple semen parameters and reduced DNA fragmentation.

PubMed ID: 35023797

ALA 600 mg/day improved sperm motility and vitality in men with idiopathic asthenozoospermia.

PubMed ID: 35442486

Improvements in anemia, inflammation and glycemic control could translate to increased vitality in dialysis patients.

PubMed ID: 34105866

Reductions in oxidative/inflammatory markers and improved mood in migraineurs support subjective vitality.

PubMed ID: 33487271

Probiotic+ALA improved weight maintenance, waist circumference and CRP after diet (supports sustained vitality).

PubMed ID: 32692358

R-ALA produced modest BMI loss and improved antioxidant markers—broad metabolic and redox benefits linked to vitality.

PubMed ID: 20034232

Marked reductions in oxidative damage after supplementation support general recovery/vitality.

PubMed ID: 32370731

Improved neuropathic symptoms and sensory function in diabetic neuropathy likely increase overall function/vitality.

PubMed ID: 29743087

Well‑controlled trial: ALA modestly enhanced weight/fat loss and improved insulin resistance during dieting—broad vitality effects.

PubMed ID: 25535146

Broad improvements (antioxidant enzymes, NIHSS, glucose/lipids) in elderly stroke patients indicate improved overall vitality.

PubMed ID: 23905488

Improvements in HbA1c, BMI and erectile function in T2DM suggest enhanced systemic vitality.

PubMed ID: 24172699

Improvements in redox, inflammation and LV function in young T1D patients point to potential overall health/vitality gains.

PubMed ID: 31021358

Multi‑ingredient supplement including ALA increased muscle mass/strength in older adults (indirect evidence).

PubMed ID: 20977356

Antioxidant supplementation including LA improved mitochondrial function breath-test markers in HIV patients.

PubMed ID: 23238616

ALA increased ALDH2 activity (mitochondrial enzyme), suggesting mitochondrial protective/energetic effects.

PubMed ID: 23905488

12‑week study in T2DM showed improved HbA1c and BMI—better glycemic control can steady energy.

PubMed ID: 25535146

Improved glucose and HOMA‑IR in stroke patients after ALA—supports more stable metabolic energy.

PubMed ID: 25753493

12‑week RCT in chronic SCI men lowered fasting glucose and anthropometrics—consistent with improved metabolic steadiness (confounded by reduced intake).

PubMed ID: 27801825

Multi‑ingredient supplement including ALA improved fasting/postprandial glycemia and HOMA‑IR, supporting steadier blood energy availability.

PubMed ID: 30286558

ALA increased TAC and reduced glucose/HOMA‑IR markers in ICU patients, consistent with more stable metabolic state.

PubMed ID: 30311825

Supplement including ALA lowered fasting glucose and HbA1c (rapid glycemic improvements imply steadier energy availability).

PubMed ID: 29743087

In overweight women ALA modestly enhanced weight/fat loss and improved HOMA‑IR during caloric restriction (supports cellular metabolic energy changes).

PubMed ID: 31343010

Improved insulin resistance/adipokines in NAFLD (metabolic improvements can reflect cellular energy handling).

PubMed ID: 34105866

Migraine trial reported improved mood/stress and antioxidant indices; these changes can reduce perceived fatigue (indirect).

PubMed ID: 35442486

Increased hemoglobin and reduced erythropoietin resistance in dialysis patients suggest reduced fatigue potential.

PubMed ID: 34997178

Migraine RCT reduced serum lactate (mitochondrial marker) and clinical migraine burden — supports cellular energy benefit.

PubMed ID: 37686725

12‑week multi‑ingredient supplement (includes ALA) produced modest but statistically significant weight and fat loss.

PubMed ID: 33487271

Combined probiotic+ALA improved weight-loss maintenance and waist circumference after an initial diet.

PubMed ID: 32692358

R-ALA produced modest but significant BMI/weight reduction over 24 weeks in overweight adults.

PubMed ID: 29743087

During hypocaloric diet ALA produced modest but statistically significant additional weight and fat mass loss vs control.

PubMed ID: 21187189

Large RCT: 1800 mg/day ALA produced modest but significant weight loss vs placebo over 20 weeks.

PubMed ID: 23905488

BMI decreased significantly in T2DM men over 12 weeks with ALA treatment.

PubMed ID: 25594166

Randomized double‑blind trial showed modestly greater weight loss with ALA during a 10‑week hypocaloric diet.

PubMed ID: 25753493

Observed reductions in body weight, BMI and waist circumference over 12 weeks with ALA, though dietary intake decreased (confounder).

PubMed ID: 28239907

8‑week RCT: oral ALA 1200 mg/d produced mild but statistically significant weight and waist reductions vs placebo.

PubMed ID: 31564281

ALA added to valsartan reduced UAER and inflammation in early diabetic kidney disease, hinting at renal protective/detox effects.

PubMed ID: 23238616

Increased ALDH2 (detoxifying mitochondrial enzyme) and lowered oxidative lipid marker—supports detox pathways.

PubMed ID: 25617577

600 mg/day ALA reduced serum iron and transferrin saturation, consistent with metal chelation/altered metal handling.

PubMed ID: 37686725

12‑week multi‑ingredient including ALA lowered ALT and EV‑miRNAs linked to fatty liver (hepatic biomarker improvement).

PubMed ID: 28116765

Renal improvements (UAER decrease) and antioxidant shifts suggest improved renal handling/clearance of damaging species.

PubMed ID: 34699040

In acute drug poisoning, ALA lowered oxidative markers vs routine care—used here in a detox/antioxidant context.

PubMed ID: 24665163

300 mg/day ALA for 3 months prevented decline or modestly improved contrast sensitivity in diabetic patients, especially at higher spatial frequencies.

PubMed ID: 27840374

100‑patient RCT in dry AMD: oral ALA increased antioxidant enzyme activity and improved vision‑related QoL and contrast sensitivity.

PubMed ID: 31243641

Multi-ingredient eye supplement containing ALA improved central macular electrophysiologic responses (functional improvement).

PubMed ID: 33514891

Topical lipoic-acid prodrug (UNR844) produced clinically meaningful and durable improvements in near vision (presbyopia).

PubMed ID: 22044044

Short antioxidant regimen including ALA improved retinal ERG oscillatory potentials and increased plasma antioxidant capacity (small study).

PubMed ID: 34128884

ALA added to pulsed radiofrequency improved pain and function in lumbar radicular pain—pain relief may extend to musculoskeletal contexts.

PubMed ID: 34649217

Oral ALA reduced idiopathic pain scores vs placebo; this can translate to general symptom relief including joint-related pain (indirect).

PubMed ID: 24477618

Oral ALA+SOD with physiotherapy produced larger reductions in neck pain and disability vs physiotherapy alone.

PubMed ID: 38138300

Rehab + supplement mix (including ALA) markedly reduced pain and improved QoL in sciatica—a musculoskeletal pain context.

PubMed ID: 14616378

Topical ALA improved photoaged facial skin (anti‑aging skin effect).

PubMed ID: 33514891

Topical lipoic-acid prodrug improved presbyopic near vision with durable effects—an age-related functional benefit.

PubMed ID: 24077434

ω‑3+ALA arm showed substantially slower cognitive and functional decline over 12 months in mild–moderate AD pilot.

PubMed ID: 31243641

Multi‑ingredient eye supplement including ALA improved macular electrophysiology in intermediate AMD (functional benefit).

PubMed ID: 32692358

R-ALA reduced oxidative stress biomarkers and produced modest BMI loss—mechanisms relevant to healthy aging.

PubMed ID: 17953631

Antioxidant regimen including ALA given with NB-UVB markedly improved vitiligo repigmentation and reduced ROS/catalase changes.

PubMed ID: 26735264

Vitiligo RCT: oral ALA as adjunct accelerated repigmentation and increased early response rates.

PubMed ID: 30564928

Triple‑blind RCT showed 6 weeks oral ALA postpartum improved cesarean scar healing and reduced niche incidence (direct tissue healing benefit).

PubMed ID: 14616378

Topical 5% ALA cream significantly improved facial skin roughness and appearance (split-face RCT).

PubMed ID: 17999779

Short-term ALA reduced exercise-induced oxidative damage and improved antioxidant enzyme responses in healthy men.

PubMed ID: 20034232

Short-term oral ALA reduced TBARS and protein carbonylation at rest and after exercise, suggesting recovery benefit.

PubMed ID: 27869661

Probiotic + ALA reduced resting circulating endotoxin and prevented exercise‑induced gut permeability increases in triathletes—supports recovery from endurance stress.

PubMed ID: 19617657

Trained men: ALA reduced markers of oxidative damage after muscle-damaging exercise and increased GSH.

PubMed ID: 25535146

Improved NIHSS and metabolic markers post‑stroke and raised antioxidant enzymes—could support cognitive/neurologic clarity.

PubMed ID: 34105866

Migraine trial reported reduced depression/anxiety/stress; improved mood/stress can secondarily improve cognitive clarity.

PubMed ID: 24077434

Combination ω‑3+ALA associated with markedly slower cognitive decline and better IADL over 12 months.

PubMed ID: 34105866

Randomized trial in episodic migraine showed significant reductions in depression, anxiety and stress scores with ALA.